Tag
Switching from daily somatropin to once-weekly somapacitan in adults with growth hormone deficiency maintains lean mass, improves functional outcomes, but may increase adiposity indices, highlighting a trade-off in metabolic effects during
In 180 adolescents and young adults with childhood-onset GH deficiency, glucagon-stimulated GH secretion was driven mainly by hypothalamic-pituitary disease severity, while BMI had little independent effect after accounting for etiology.
Skytrofa, a once-weekly injectable growth hormone, is FDA-approved for adult GHD, offering improved adherence and positive metabolic outcomes. Clinical trials show superior efficacy and favorable safety compared to daily somatropin.
Once-weekly lonapegsomatropin (Skytrofa) is now FDA-approved for adult growth hormone deficiency, offering a more convenient alternative to daily injections with demonstrated efficacy and safety.
